久久综合日本久久综合,亚洲成AV人片在线观看天堂无码,国产在线视频不卡一区二区,久久久久看免费高清特色大片

武漢佰樂博生物技術(shù)有限公司
   
     
聯(lián)系熱線
  • 聯(lián)系人:方經(jīng)理
  • 電 話:027-65279366
  • 郵箱:products@biolabreagent.com
  • 地 址:武漢市東湖新技術(shù)開發(fā)區(qū)神墩四路666號C棟

艾沃利單抗 ,Omburtamab, AntibodySystem Laboratories

發(fā)表時間:2023-05-10

標(biāo)題:艾沃利單抗 Omburtamab,CAS:1895083-75-6, AntibodySystem Laboratories


貨號:DHJ04002

產(chǎn)品鏈接:http://www.atagenix.com/product_detail-75194.html

別名:8H9, Mab 8H9, CAS: 1895083-75-6

簡介:

Omburtamab 是一種 anti-CD276 (也被稱為 B7-H3) 的單克隆抗體,CD276 是一種在人類實體腫瘤中表達的 B7/CD28 免疫球蛋白家族成員。Omburtamab 可以與腫瘤組織相結(jié)合,用于各種癌癥的研究。

貨號:DHJ04002

產(chǎn)品品牌:Antibodysystem

通用名:Omburtamab

純度:>95% by SDS-PAGE.

濃度:1mg/ml

Formulationicon:0.01M PBS, pH 7.4.

別名:8H9, Mab 8H9

靶點;物種:Human CD276/B7-H3

種類:Mus musculus

受體鑒定:IgG1-kappa

CAS: 1895083-75-6

存儲條件:

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

參考文獻:

Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies. PMID: 36371226
Antibodies to watch in 2020. PMID: 31847708
Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine. PMID: 31481583
IntraOmmaya compartmental radioimmunotherapy using 131I-omburtamab-pharmacokinetic modeling to optimize therapeutic index. PMID: 33047248
Biodistribution and Dosimetry of Intraventricularly Administered 124I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors. PMID: 31405921
Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. PMID: 33514401
Biodistribution and Radiation Dosimetry of Intraperitoneally Administered 124I-Omburtamab in Patients with Desmoplastic Small Round Cell Tumors. PMID: 34857661
B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study. PMID: 33119478
Outcomes of intraventricular 131-I-omburtamab and external beam radiotherapy in patients with recurrent medulloblastoma and ependymoma. PMID: 36853490
Radioimmunoscintigraphy and pre-treatment dosimetry of 131I-omburtamab for planning treatment of leptomeningeal disease. PMID: 36759197
Antibodies to watch in 2019. PMID: 30516432
Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes. PMID: 30879172
Mast cell proliferation in the cerebrospinal fluid after intraventricular administration of anti-B7H3 immunotherapy. PMID: 33533945
Repeat convection-enhanced delivery for diffuse intrinsic pontine glioma. PMID: 32977309
Effective killing of cells expressing CD276 (B7-H3) by a bispecific T cell engager based on a new fully human antibody. PMID: 34601396
Evaluation of a patient-specific algorithm for predicting distribution for convection-enhanced drug delivery into the brainstem of patients with diffuse intrinsic pontine glioma. PMID: 33990084

聯(lián)系方式
手機:18162686757
微信掃一掃
大港区| 合山市| 聊城市| 汉川市| 汤原县| 灵山县| 夹江县| 饶平县| 且末县| 渭南市| 嘉定区| 五大连池市| 丰城市| 乐都县| 会泽县| 嵊州市| 彝良县| 夹江县| 乌兰察布市| 余江县| 始兴县| 门头沟区| 丰镇市| 禹州市| 信宜市| 富锦市| 布尔津县| 五华县| 宁城县| 舟曲县| 金川县| 临猗县| 五华县| 务川| 青川县| 康保县| 永善县| 邵东县| 稷山县| 禹城市| 莲花县|